July 18th 2016EP. 1: Pathophysiology and Treatment Landscape of CLL
July 18th 2016EP. 2: Increased Use of Targeted Therapies in CLL
July 18th 2016EP. 3: Health Plans Encourage Use of Diagnostic Tests in CLL
July 18th 2016EP. 4: Impact of Major Trials on CLL Treatment
July 18th 2016EP. 5: Pathophysiology, Prognostic Factors, and Potential Risks That Influence Treatment in CLL
July 18th 2016EP. 6: Flexibility in Treatment Options for CLL
July 18th 2016EP. 7: Combination Treatments in CLL
July 18th 2016EP. 8: Factors That Influence Up-front Therapy and Sequencing in CLL
July 18th 2016EP. 9: Impact of Novel Agents on Coverage Decisions in CLL
July 18th 2016EP. 10: Efficacy and Safety Considerations to Improve the Value of Treatment in CLL
July 18th 2016EP. 11: RESONATE-2 Trial: Safety and Efficacy Updates
July 18th 2016EP. 12: Patient Selection for Treatment With Ibrutinib in CLL
July 18th 2016EP. 13: Treatment Options for Older Patients With CLL
July 18th 2016EP. 14: Expanding Options in Treating CLL
July 18th 2016EP. 15: How Do Payers Assess Value of Treatments in CLL?
July 18th 2016EP. 16: The Changing Treatment Paradigm in CLL
July 18th 2016EP. 17: Safety of CLL Treatment and Reimbursement
July 18th 2016EP. 18: Safety and Efficacy Considerations in CLL
July 18th 2016EP. 19: Looking to the Future in CLL Treatments
July 18th 2016EP. 20: Value of Real-World Data in CLL Treatment
July 18th 2016EP. 21: Outcomes From the RESONATE 2 and HELIOS Trials - Clinical Impact
July 18th 2016EP. 22: Unmet Needs and the Increased Use of Targeted Therapy in CLL
July 18th 2016EP. 23: Diagnostic Testing and Evidence-Based Treatment in Cancer Care
July 18th 2016EP. 24: Influence of Treatment Modality on Outcomes in CLL
July 18th 2016EP. 25: Weighing the Value of Treatments in CLL
